<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p59" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_59{left:130px;bottom:1196px;letter-spacing:-0.15px;}
#t2_59{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_59{left:141px;bottom:1104px;letter-spacing:-0.01px;}
#t4_59{left:248px;bottom:1104px;letter-spacing:0.12px;}
#t5_59{left:141px;bottom:1072px;letter-spacing:0.22px;}
#t6_59{left:250px;bottom:1067px;letter-spacing:-0.01px;}
#t7_59{left:250px;bottom:1047px;letter-spacing:-0.01px;}
#t8_59{left:250px;bottom:1028px;letter-spacing:-0.01px;}
#t9_59{left:143px;bottom:1024px;}
#ta_59{left:141px;bottom:989px;letter-spacing:-0.03px;}
#tb_59{left:248px;bottom:989px;letter-spacing:-0.03px;}
#tc_59{left:141px;bottom:941px;letter-spacing:-0.28px;}
#td_59{left:248px;bottom:914px;letter-spacing:-0.04px;}
#te_59{left:141px;bottom:843px;letter-spacing:-0.01px;}
#tf_59{left:248px;bottom:843px;letter-spacing:0.12px;}
#tg_59{left:141px;bottom:811px;letter-spacing:0.22px;}
#th_59{left:250px;bottom:806px;letter-spacing:-0.01px;}
#ti_59{left:250px;bottom:787px;letter-spacing:-0.01px;}
#tj_59{left:250px;bottom:767px;letter-spacing:-0.01px;}
#tk_59{left:143px;bottom:763px;}
#tl_59{left:141px;bottom:728px;letter-spacing:-0.03px;}
#tm_59{left:248px;bottom:728px;letter-spacing:-0.03px;}
#tn_59{left:141px;bottom:681px;letter-spacing:-0.3px;}
#to_59{left:250px;bottom:653px;letter-spacing:-0.04px;}
#tp_59{left:141px;bottom:576px;letter-spacing:-0.01px;}
#tq_59{left:248px;bottom:576px;letter-spacing:-0.01px;}
#tr_59{left:141px;bottom:544px;letter-spacing:-0.03px;}
#ts_59{left:250px;bottom:539px;letter-spacing:-0.01px;}
#tt_59{left:250px;bottom:520px;letter-spacing:-0.01px;}
#tu_59{left:250px;bottom:500px;letter-spacing:-0.01px;}
#tv_59{left:250px;bottom:481px;letter-spacing:-0.01px;}
#tw_59{left:143px;bottom:496px;letter-spacing:-0.3px;}
#tx_59{left:248px;bottom:445px;letter-spacing:-0.03px;}
#ty_59{left:250px;bottom:415px;letter-spacing:-0.04px;}
#tz_59{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_59{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_59{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_59{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_59{font-size:8px;font-family:NotoSans-Regular_7j-;color:#000;}
.s4_59{font-size:28px;font-family:NotoSans-Regular_7j-;color:#000;}
.s5_59{font-size:10px;font-family:NotoSans-Regular_7j-;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts59" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg59Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg59" style="-webkit-user-select: none;"><object width="908" height="1286" data="59/59.svg" type="image/svg+xml" id="pdf59" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_59" class="t s0_59">7.3. Fundamental considerations of multimodal therapy approaches </span><span id="t2_59" class="t s1_59">59 </span>
<span id="t3_59" class="t s2_59">7.16. </span><span id="t4_59" class="t s1_59">Evidence-based recommendation </span>
<span id="t5_59" class="t s3_59">Recommendation level </span>
<span id="t6_59" class="t s2_59">Neoadjuvant chemotherapy should not be performed before planned definitive radio- or </span>
<span id="t7_59" class="t s2_59">chemoradiotherapy, except for the purpose of selection between laryngectomy and radio- or </span>
<span id="t8_59" class="t s2_59">chemoradiotherapy. </span>
<span id="t9_59" class="t s4_59">A </span>
<span id="ta_59" class="t s5_59">Level of Evidence </span><span id="tb_59" class="t s5_59">[187, 188, 195, 196] </span>
<span id="tc_59" class="t s4_59">1a </span>
<span id="td_59" class="t s5_59">Strong consensus: 100% </span>
<span id="te_59" class="t s2_59">7.17. </span><span id="tf_59" class="t s1_59">Evidence-based recommendation </span>
<span id="tg_59" class="t s3_59">Recommendation level </span>
<span id="th_59" class="t s2_59">If neoadjuvant chemotherapy is indicated for the purpose of selecting between </span>
<span id="ti_59" class="t s2_59">laryngectomy and radio- or chemoradiotherapy, it should be performed with up to 3 cycles </span>
<span id="tj_59" class="t s2_59">of cisplatin, docetaxel and +/- 5FU. </span>
<span id="tk_59" class="t s4_59">B </span>
<span id="tl_59" class="t s5_59">Level of Evidence </span><span id="tm_59" class="t s5_59">[197, 198] </span>
<span id="tn_59" class="t s4_59">1b </span>
<span id="to_59" class="t s5_59">Strong consensus: 100% </span>
<span id="tp_59" class="t s2_59">7.18. </span><span id="tq_59" class="t s2_59">Evidence-based statement </span>
<span id="tr_59" class="t s5_59">Level of Evidence </span>
<span id="ts_59" class="t s2_59">Locoregional tumor control and overall survival are improved by the simultaneous </span>
<span id="tt_59" class="t s2_59">administration of cetuximab with radiotherapy in </span>
<span id="tu_59" class="t s2_59">squamous cell carcinoma of the head and neck region. However, in the subgroup of </span>
<span id="tv_59" class="t s2_59">laryngeal carcinomas, this effect is not statistically significant. </span>
<span id="tw_59" class="t s4_59">1b </span>
<span id="tx_59" class="t s5_59">[194, 199] </span>
<span id="ty_59" class="t s5_59">Strong consensus: 100% </span>
<span id="tz_59" class="t s0_59">Â© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
